ATRO Medical, a Radboudumc and DSM spin-off, is based in Uden and has an office in Nijmegen, where the company benefits from the expertise and facilities of Radboudumc. Jan Hunik, co-founder and CEO: "I am very pleased with this investment round and welcomes the trust in the Trammpolin® device at this stage of the development. The funds raised will enable the company to execute a second clinical study to demonstrate its potential to improve the quality of lives of patients".
Read the full article on ATRO Medical
image courtesy of ATRO Medical
Related news items

Job opportunity: Program Manager Health Incubator at SMB
17 January 2023Science Meets Business (SMB) is looking for a community builder to manage and expand the incubator and maintain relationships with the stakeholders.
read more
Help Cell4Pharma to reduce animal testing in drug development
21 December 2022More than 50 million animals are used for medical experiments each year in the United States alone. But we have an alternative!
read moreAftermovie Investment Day 2022 and a new date for 2023!
13 December 2022Over 100 scientists, investors, and entrepreneurs came together to accelerate innovation in healthcare by creating new business opportunities and forging strong public-private partnerships.
read moreJoining forces increases innovation Janssen and Radboud
1 December 2022Dr. Eng Kinga Matuła (KM), specialist in single-cell multi-omics and Jeroen Van Houdt (JH), Omics group leader at Janssen Pharmaceutica, answer three pressing questions about the successful collaboration in the single-cell technology project.
read moreEnzyre closes Series A financing round of €12M to advance pioneering diagnostic technology platform for hemophilia patients
2 November 2022Enzyre has announced that it has successfully raised €12 million in a Series A financing led by new investor, Oost NL, with participation from i&i Biotech Fund, Demcon Investment, Takeda Ventures, and Novalis Biotech. Part of the funding is an Innovation Credit from the Dutch Government.
read more